Health-related quality of life (HRQoL) impact of pembrolizumab (P) versus chemotherapy (C) as first-line (1L) treatment in PD-L1-positive advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma Meeting Abstract
| Authors: | Van Cutsem, E.; Valderrama, A.; Bang, Y. J.; Fuchs, C.; Shitara, K.; Janjigian, Y. Y.; Qin, S.; Larson, T.; Shankaran, V.; Stein, S.; Norquist, J. M.; Kher, U.; Shah, S.; Alsina, M. |
| Abstract Title: | Health-related quality of life (HRQoL) impact of pembrolizumab (P) versus chemotherapy (C) as first-line (1L) treatment in PD-L1-positive advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma |
| Meeting Title: | 44th ESMO Congress (ESMO 2019) |
| Journal Title: | Annals of Oncology |
| Volume: | 30 |
| Issue: | Suppl. 5 |
| Meeting Dates: | 2019 Sep 27-Oct 1 |
| Meeting Location: | Barcelona, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2019-10-01 |
| Start Page: | mdz394.036 |
| Language: | English |
| ACCESSION: | WOS:000491295500169 |
| PROVIDER: | wos |
| DOI: | 10.1093/annonc/mdz394.036 |
| Notes: | Meeting Abstract: LBA45 -- Appears on page v879 of the abstract book -- Source: Wos |
